Javier P Gisbert
Overview
Explore the profile of Javier P Gisbert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
597
Citations
10260
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cervera-Seco L, Baldan-Martin M, Fernandez-Tome S, Ortega Moreno L, Lozano J, Aransay A, et al.
Inflamm Bowel Dis
. 2025 Mar;
PMID: 40067082
Background: MicroRNAs (miRNAs) play a key role in regulating gene expression in Crohn's disease (CD). Although several studies have identified miRNAs with biomarker potential, an exhaustive characterization of the miRNAome...
2.
Casas Deza D, Alcedo J, Lafuente M, Lopez F, Perez-Aisa A, Pavoni M, et al.
Am J Gastroenterol
. 2025 Feb;
PMID: 39902822
Introduction: To evaluate the prescription patterns, effectiveness, and safety of adding probiotics to Helicobacter pylori eradication therapy, in Europe. Methods: International, prospective, noninterventional registry of the clinical practice of the...
3.
Calafat M, Suria C, Mesonero F, de Francisco R, Yague Caballero C, de la Pena L, et al.
Am J Gastroenterol
. 2025 Jan;
120(2):431-439.
PMID: 39888687
Introduction: The coexistence of HIV infection and inflammatory bowel disease (IBD) is uncommon. Data on the impact of HIV on IBD course and its management are scarce. The aim of...
4.
Janus kinase inhibitors in the management of acute severe ulcerative colitis: a comprehensive review
Gisbert J, Chaparro M
J Crohns Colitis
. 2025 Jan;
19(2).
PMID: 39886994
Background: One-third of patients with acute severe ulcerative colitis (ASUC) are steroid-refractory. Cyclosporine and infliximab are currently the mainstays of salvage therapy. Janus kinase inhibitors (JAKi) could play a role...
5.
Baldan-Martin M, Azkargorta M, Lapitz A, Ortega Moreno L, Iloro I, Fernandez-Tome S, et al.
Int J Mol Sci
. 2025 Jan;
26(2.
PMID: 39859242
The proteomic analysis of serum extracellular vesicles (EVs) could be a useful tool for studying the pathophysiology of Crohn's disease (CD) and ulcerative colitis (UC), as well as for biomarker...
6.
Gisbert J, Chaparro M
Gastroenterol Hepatol
. 2025 Jan;
:502363.
PMID: 39855296
Etrasimod is a synthetic, non-biological, orally administered small molecule sphingosine-1-phosphate receptor (S1PR) modulator. Etrasimod was approved by the Food and Drug Administration in 2023 and by the European Medicine Agency...
7.
Gisbert J, Donday M, Riestra S, Lucendo A, Benitez J, Navarro-Llavat M, et al.
Gut
. 2025 Jan;
74(3):387-396.
PMID: 39794921
Background And Objectives: Primary objectives: to compare the rates of sustained clinical remission at 12 months in patients treated with antitumour necrosis factor (anti-TNF) and immunomodulators who withdraw anti-TNF treatment...
8.
Giordano A, Perez-Martinez I, Gisbert J, Ricart E, Martin-Arranz M, Mesonero F, et al.
Am J Gastroenterol
. 2025 Jan;
120(1):194-203.
PMID: 39745305
Introduction: Crohn's disease (CD) varies by location, potentially affecting therapy efficacy and surgery risk, although research on this topic is conflicting. This study aims to investigate the independent association between...
9.
Garcia M, Brenes Y, Vicuna M, Bermejo F, Sierra-Ausin M, Vicente R, et al.
Am J Gastroenterol
. 2024 Nov;
PMID: 39588977
Introduction: Real-world data on the effectiveness of upadacitinib for inflammatory bowel disease (IBD) are limited. To assess upadacitinib persistence, effectiveness, and safety in a real-world scenario. Methods: Retrospective multicenter study...
10.
Benito B, Nyssen O, Gisbert J
Helicobacter
. 2024 Nov;
29(6):e13148.
PMID: 39533409
Background: The efficacy of Helicobacter pylori (H. pylori) eradication therapies encompassing one or more antibiotics and a proton pump inhibitor (PPI) has lately decreased. Vonoprazan (VPZ), a potassium-competitive acid blocker,...